Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IM96
- Development stage
- Phase 1
- Lead developer
- Immunochina Pharmaceuticals
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
IM96 is an autologous chimeric antigen receptor T-cell (CAR-T) therapy under development for the treatment of solid tumors, primarily metastatic colorectal cancer. It targets guanylyl cyclase 2C (GUCY2C or GC-C), a gastrointestinal-expressed antigen found on tumor cells. The therapy involves engineering a patient's own T cells to express a CAR that recognizes and binds to GUCY2C, enabling targeted immune-mediated destruction of cancer cells. IM96 is being developed by Beijing Imunopharm Technology in collaboration with Peking University Cancer Hospital and has received clinical trial approval from China's National Medical Products Administration for use in metastatic colorectal cancer. Early phase I data show limited but notable efficacy in heavily pretreated patients[1][3][4].
- Other names
- IM96 CAR-T细胞
02
Targets
GUCY2C (Guanylate cyclase C receptor)
Beyond the preview
Go deeper on IM96.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IM96.